Show simple item record

dc.contributor.authorSalmanton-García, Jon
dc.contributor.authorHoenigl, Martin
dc.contributor.authorGangneux, Jean-Pierre
dc.contributor.authorSegal, Esther
dc.contributor.authorAlastruey-Izquierdo, Ana 
dc.contributor.authorArikan Akdagli, Sevtap
dc.contributor.authorLagrou, Katrien
dc.contributor.authorÖzenci, Volkan
dc.contributor.authorVena, Antonio
dc.contributor.authorCornely, Oliver A
dc.date.accessioned2023-08-25T07:54:41Z
dc.date.available2023-08-25T07:54:41Z
dc.date.issued2023-01
dc.identifier.citationLancet Microbe. 2023 Jan;4(1):e47-e56.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16341
dc.description.abstractAccess to the appropriate tools is crucial for early diagnosis and clinical management of invasive fungal infections. This Review aims to describe the invasive fungal infection diagnostic capacity of Europe to better understand the status and the most pressing aspects that need improvement. To our knowledge, this is the first time that the mycological diagnostic capability and access to antifungal treatments of institutions has been evaluated at a pan-European level. Between Nov 1, 2021, and Jan 31, 2022, 388 institutions in Europe self-assessed their invasive fungal infection management capability. Of the 388 participating institutions from 45 countries, 383 (99%) had access to cultures, 375 (97%) to microscopy, 363 (94%) to antigen-detection assays, 329 (85%) to molecular tests (mostly PCR), and 324 (84%) to antibody tests for diagnosis and management. With the exception of microscopy, there were considerable differences in access to techniques among countries according to their gross domestic product. At least one triazole was available in 363 (94%) of the institutions, one echinocandin in 346 (89%), and liposomal amphotericin B in 301 (78%), with country gross domestic product-based differences. Differences were also observed in the access to therapeutic drug monitoring. Although Europe is well prepared to manage invasive fungal infections, some institutions do not have access to certain diagnostic tools and antifungal drugs, despite most being considered essential by WHO. These limitations need to be overcome to ensure that all patients receive the best diagnostic and therapeutic management.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAntifungal Agents es_ES
dc.subject.meshInvasive Fungal Infections es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMycology es_ES
dc.subject.meshEchinocandins es_ES
dc.subject.meshEurope es_ES
dc.titleThe current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology surveyes_ES
dc.typereview articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID36463916es_ES
dc.format.volume4es_ES
dc.format.number1es_ES
dc.format.pagee47-e56es_ES
dc.identifier.doi10.1016/S2666-5247(22)00261-0es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2666-5247es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/S2666-5247(22)00261-0es_ES
dc.identifier.journalThe Lancet. Microbees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional